BioSpace News Archive

Mayo Clinic, Hibiscus BioVentures (Hibiscus) and Innoforce announce the launch of Mayflower BioVentures, a cell and gene therapy accelerator dedicated to identifying and forming companies around technologies that address unmet patient needs.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today published its financial results for the quarter ended June 30, 2022 and provided a business update.

A newly published Random Clinical Trial (RCT) provides additional support for statements Xlear made about the use of nasal hygiene as an added layer of protection in combatting the SARS-CoV-2 virus.

Janux Therapeutics, Inc. announced that Janux management will participate and present at two upcoming investor conferences.

Baxter International Inc. (NYSE:BAX), a leader in innovative technology for medication delivery, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its new Novum IQ syringe infusion pump (SYR) with Dose IQ Safety Software, representing Baxter’s latest developments for infusion therapy.

Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce its continued accumulation of international patent recognition with the receipt of its 27th worldwide patent granted in Mexico under registration #390001.

The Heart Failure Society of America (HFSA) is pleased to announce the Late Breaking Clinical Trials coming to its Annual Scientific Meeting (ASM), which will take place September 30 – October 3, 2022, at the Gaylord National Harbor, just outside of Washington, DC.

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or Co-Dx), announced today that it will be hosting a booth at the upcoming Medical Fair Asia 2022 trade show held August 31-September 2 at the Marina Bay Sands in Singapore.

The Lupus Foundation of America and Lupus Canada are proud to announce that the 2022 Lupus Canada Catalyst Award has been awarded to Éric Boilard, PhD, Professor at Université Laval in the Department of Microbiology and Immunology and researcher at Centre de Recherche du CHU de Québec, for his study examining the role of platelets in lupus.

Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, Sept. 13, 2022. Anat Ashkenazi, Lilly’s senior vice president and chief financial officer, will participate in a fireside chat at 11:10 a.m., Eastern time.